Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3475A subcutaneous versus pembrolizumab intravenous first-line trial in PD-L1 high metastatic NSCLC
CTR20244069Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: AUC0-6 weeks in cycle 1 and Steady-state trough concentration in cycle 3. Started Jan 2025; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244069.